Biomea Fusion to Present Three Late-Breaking Icovamenib Posters on T1D and T2D
BMEA•Biomea Fusion will present three icovamenib abstracts as late-breaking posters at the American Diabetes Association 86th Scientific Sessions, including glycemic improvement data in T2D patients on GLP-1 therapy and insulin secretion results in T1D from COVALENT-111 and COVALENT-112 studies. All presentations are scheduled June 7, with materials available June 5.
1. Poster Presentations at ADA 86th Scientific Sessions
Three icovamenib abstracts were selected for late-breaking poster sessions 2857-LB, 2858-LB and 2871-LB at the American Diabetes Association 86th Scientific Sessions, with presentations scheduled for June 7 by Juan Pablo Frías, M.D., and Mini Balakrishnan, Ph.D.
2. Icovamenib Clinical Data Highlights
The COVALENT-111 subgroup analysis will report glycemic improvements in type 2 diabetes patients on GLP-1 therapy, while the COVALENT-112 study will detail enhanced endogenous insulin secretion in type 1 diabetes; a third poster will explore menin inhibition mechanisms supporting metabolic health.
3. Material Release and Availability
All presentations become publicly available following embargo lift on June 5 at 6:30 PM CT, with materials to be accessible on the Diabetes journal website and in the Investors & Media section of Biomea Fusion’s site.
